COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1 [0.03%]
风湿性关节炎患者中的新冠病毒疫苗诱导的T细胞反应：ChAdOx1疫苗优势诱导
Benazir Saleem,Rebecca L Ross,Laurence Duquenne et al.
Benazir Saleem et al.
The Lancet Rheumatology
The Lancet Rheumatology
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study [0.03%]
英国生物银行中痛风与冠状病毒疾病-19诊断及死亡风险的相关性研究
Ruth K Topless,Angelo Gaffo,Lisa K Stamp et al.
Ruth K Topless et al.
Background: There is a paucity of data on outcomes for people with gout and COVID-19. We aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19-related death, and to test for sex- and drug-sp...
Christoffer B Nissen,Oliver Hendricks,Karen Schreiber
Christoffer B Nissen
Risk factors for dislocation after primary total hip replacement: meta-analysis of 125 studies involving approximately five million hip replacements [0.03%]
初次全髋置换术后脱位的风险因素：基于125项研究约50万例患者的meta分析
Setor K Kunutsor,Matthew C Barrett,Andrew D Beswick et al.
Setor K Kunutsor et al.
Background: Dislocation following total hip replacement (THR) is associated with repeated hospitalisations and substantial costs to the health system. Factors influencing dislocation following primary THR are not well und...
[This corrects the article DOI: 10.1016/S2665-9913(21)00251-4.]. © 2022 Elsevier Ltd. All rights reserved.
Published Erratum
The Lancet. Rheumatology. 2022 Mar;4(3):e174. DOI:10.1016/S2665-9913(22)00025-X 2022
Is social support associated with patient-reported outcomes after joint replacement? A systematic review and meta-analysis [0.03%]
社会支持与关节置换患者的结局报告相关吗？系统回顾及荟萃分析
V Wylde,S K Kunutsor,E Lenguerrand et al.
V Wylde et al.
Background: Identifying prognostic factors for outcomes after joint replacement could improve the provision of stratified care. This systematic review evaluated whether social support is a prognostic factor for better pat...
Jessica K Gordon,Kimberly Showalter,Yin Wu et al.
Jessica K Gordon et al.
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease [0.03%]
风湿性和肌肉骨骼疾病患者接种两剂新冠病毒mRNA疫苗后6个月的抗体持久性
Sarah Frey,Teresa Po-Yu Chiang,Caoilfhionn M Connolly et al.
Sarah Frey et al.